A multicenter phase II trial of losoxantrone (DuP-941) in hormone- refractory metastatic prostate cancer

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1333-1336

  Huan, Susan D ^a   Natale, Ronald B ^b   Stewart, David J ^a   Sartiano, George P ^c   Stella, Philip J ^d   Roberts, John D ^e   Symes, Aston L ^f   Finizio, Michael ^f  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d McAuley Cancer Care Center   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOSOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DYSPNEA; FEMALE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; VOMITING;

AGED; AGED, 80 AND OVER; ANOREXIA; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DIARRHEA; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HEART VENTRICLES; HEMATOLOGIC DISEASES; HORMONES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRAZOLES; PYRAZOLONES; STOMATITIS; SURVIVAL ANALYSIS; VOMITING;

EID: 0034092595     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Eisenberger, M. A., and Abrams, J. S. Chemotherapy for prostatic carcinoma. Semin. Urol., 6: 303-310, 1988.
2. DeWys, W. D., Bauer, M., Colsky, J., Cooper, R. A., Creech, R., and Carbone, P. P. Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer - progress report. Cancer Treat. Rep., 61: 325-328, 1977.
3. Francini, G., Petrioli, R., Manganelli, A., Cintorino, M., Marsili, S., Aquino, A., and Mondillo, S. Weekly chemotherapy in advanced prostate cancer. Br. J. Cancer, 67: 1430-1436, 1993.
4. Eagan, R. T., Hahn, R. G., and Myers, R. P. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Cancer Treat. Rep., 60: 115-117, 1976.
5. Torti, F. M., Aston, D., Lum, B. L., Kohler, M., Williams, R., Spaulding, J. T., Shortliffe, L., and Freiha, F. S. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J. Clin. Oncol., 1: 477-482, 1983.
6. O'Bryan, R. M., Baker, L. H., Gottlieb, J. F., Rivkin, S. E., Balcerzak, S. P., Grumet, G. N., Salmon, S. E., Moon, T. E., and Hoogstraten, B. Dose response evaluation of adriamycin in human neoplasia. Cancer (Phila.), 39: 1940-1948, 1977.
7. Gogas, H., and Mansi, J. L. The anthrapyrazoles. Cancer Treat. Rev., 21: 541-552, 1996.
8. Frank, P., and Novak, R. F. Effects of anthrapyrazole antineoplastic agents on lipid peroxidation. Biochem. Biophys. Res. Commun., 140: 797-807, 1986.
9. Graham, M. A., Newell, D. R., Butler, J., Hoey, B., and Patterson, L. H. The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsomes and cytochrome P-450 reductase mediated free radical processes. Biochem. Pharmacol., 36: 3345-3351, 1987.
10. Leteurtre, F., Kohlhagen, G., Paull, K. D., and Pommier, Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (losoxantrone) in the National Cancer Institute Preclinical Antitumor Drug Discovery Screen. J. Natl. Cancer Inst., 86: 1239-1244, 1994.
11. Bélanger, K., Jolivet, J., Maroun, J., Stewart, D., Grillo-Lopez, A., Whitfield, L., Wainman, N., and Eisenhauer, E. Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole. Investig. New Drugs, 11: 301-308, 1993.
12. Talbot, D. C., Smith, I. E., Mansi, J. L., Judson, I., Calvert, A. H., and Ashley, S. E. Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer. J. Clin. Oncol., 9: 2141-2147, 1991.
13. Vandenberg, T., ten Bokkel Huinink, W., Hedley, D., Panasci, L., Verma, S., Calvert, H., Francher, D., Azarnia, N., Sisk, R., and Symes, A. A Phase II study of DUP941 in advanced breast cancer patients with no prior chemotherapy. Cancer Investig., 12 (Suppl. 1): 13-14, 1994.
14. Aaronson, N. K., Ahmedzai S., Bergman, B., Bullinger, M., Cull. A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., de Haes, J. C. J. M., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P. B., Schraub, S., Sneeuw, K., Sullivan, M., and Takeda, F. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international trials in oncology. J. Natl. Cancer Inst., 85: 365-376, 1993.
15. Toxicity Criteria Reference. Modification of the February 1988 recommendations of representatives of the National Cancer Institute's clinical cooperative groups and the cancer treatment evaluation program. NCI, NIH, DHHS, 1998.
16. Fleming, T. One-sample multiple testing procedure for Phase II clinical trials: Biometrics, 38: 143-151, 1982.
17. Legha, S. S., Benjamin, R. S., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S. L., Blumenschein, G. R., and Freireich, E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med., 96: 133-139, 1982.
18. Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rev, M., Sanger, J., Kramer, E., Ferrans, V., Hochster, H., Meyers, M., Blum, R. H., Feit, F., Attubato, M., Burrows, W., and Muggia, F. M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol., 10: 117-127, 1992.
19. Moore, M. J., Osoba, D., Murphy, K., Tannock, I. F., Armitage, A., Findlay, B., Coppin, C., Neville, A., Venner, P., and Wilson, J. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J. Clin. Oncol., 12: 689-694, 1994.
20. Tannock, I. F., Osoba, D., Stockier, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M. L., and Murphy, K. C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol., 14: 1756-1764, 1996.